Time: 10.00 - 12.00 CEST, June 15th 2020 On June 15, Arocell AB provides a live broadcast business update with subsequent question time led by Redeye’s analyst Oscar Bergman. CEO Michael Brobjer, together with parts of the management team, will among other things...
Link
Two abstracts accepted for the American Association of Cancer Research 2020 (AACR 2020) has now been published online. The first study entitled “Evaluation of TK1 protein changes using the AroCell TK 210 ELISA in an acute myeloid leukemia (AML) xenograft model during...
Redeye adds a new note to the previous analysis of Arocell on their website. See full here: Redeye.se
Inhibitors of Cyclin Dependent Kinases type 4 and 6 (CDK 4/6Is) have revolutionised the therapy of breast cancer. Combined with anti-oestrogen therapy they have significantly extended the mean and median life expectancies of women with breast cancer. This combination...
Or read it at DI.se
IDL Biotech meddelar att de har tecknat ett avtal med Beckman Coulter om licensiering av IDL Biotechs samtliga tumörmarkörer på den manuella plattformen radioimmunoassay (IRMA). Licensavtalet ger Beckman Coulter globala försäljningsrättigheter och möjliggör för IDL...
On September 17, 2019, IDL Biotech will launch the company's rapid test for typhoid fever, TUBEX TF, in Kenya. Read more here
